NOVO NORDISK A/S Bagsværd, Denmark, 20 February 2015 - Novo Nordisk today announced that it has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting GLP-1 analogue semaglutide, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks.
Further information
| Media: | ||
| Mike Rulis | +45 3079 3573 | mike@novonordisk.com |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com: mailto:krop@novonordisk.com |
| Jannick Lindegaard Denholt | +45 3079 8519 | jlis@novonordisk.com: mailto:jlis@novonordisk.com |
| Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com: mailto:dabo@novonordisk.com |
| Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com: mailto:mrz@novonordisk.com |
| Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com: mailto:fdni@novonordisk.com |
Company announcement No 14 / 2015
Company announcement No 14 / 2015:
http://hugin.info/2013/R/1896081/672652.pdf
http://hugin.info/2013/R/1896081/672652.pdf
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
HUG#1896081
